Evidence map›Paper›PMID 28114990›Full record

ArticleMalaria journal2017

Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine is associated with increased prevalence of Pfdhfr mutations in Bobo-Dioulasso, Burkina Faso.

Mamoudou Cisse, Gordon A Awandare, Alamissa Soulama, Halidou Tinto, Marie-Pierre Hayette, Robert T Guiguemdé

Abstract read
In one paragraph

Article in Malaria journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Infection and drug resistance · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The genomic architecture of antimalarial drug resistance.Briefings in functional genomics · 2019
    Review
  14. Mutation Profile ofAntimicrobial agents and chemotherapy · 2019
    Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mamoudou CisseLaboratory of Parasitology and Entomology, Centre MURAZ, 01 BP 390, Bobo-Dioulasso, Burkina Faso. cisse_m@yahoo.fr.ORCID 0000-0001-8512-8561
Gordon A AwandareWest African Centre for Cell Biology of Infectious Pathogens, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.
Alamissa SoulamaLaboratory of Parasitology and Entomology, Centre MURAZ, 01 BP 390, Bobo-Dioulasso, Burkina Faso.
Halidou TintoDepartment of Clinical Research, Centre MURAZ, Bobo-Dioulasso, Burkina Faso.
Marie-Pierre HayetteLaboratory of Clinical Microbiology, University Hospital of Liège, Liège, Belgium.
Robert T GuiguemdéLaboratory of Parasitology and Entomology, Centre MURAZ, 01 BP 390, Bobo-Dioulasso, Burkina Faso.

Funding

Wellcome TrustWellcome Trust 107755/Z/15/Z
6 · The paper itself

Abstract

backgroundThe impact of sulfadoxine-pyrimethamine (SP) used as intermittent preventive treatment during pregnancy (IPTp-SP) on mutant parasite selection has been poorly documented in Burkina Faso. This study sought first to explore the relationship between IPTp-SP and the presence of mutant parasites. Second, to assess the relationship between the mutant parasites and adverse pregnancy outcomes.

methodsFrom September to December 2010, dried blood spots (DBS) were collected during antenatal care visits and at delivery from 109 pregnant women with microscopically confirmed falciparum malaria infection. DBS were analysed by PCR-restriction fragment length polymorphism (PCR-RFLP) for the polymorphisms at codons 51, 59, 108, and 164 of the Pfdhfr gene and codons 437 and 540 in the Pfdhps gene.

resultsBoth the Pfdhfr and Pfdhps genes were successfully genotyped in 92.7% (101/109) of the samples. The prevalence of Pfdhfr mutations N51I, C59R and S108N was 71.3, 42.6 and 64.4%, respectively. Overall, 80.2% (81/101) of samples carried the Pfdhps A437G mutation. None of the samples had the Pfdhfr I164L and the Pfdhps K540E mutations. The prevalence of the triple mutation N51I + C59R + S108N was 25.7% (26/101). The use of IPTp-SP was associated with a threefold increased odds of Pfdhfr C59R mutation [crude OR 3.29; 95% CI (1.44-7.50)]. Pregnant women with recent uptake of IPTp-SP were at higher odds of both the Pfdhfr C59R mutation [adjusted OR 4.26; 95% CI (1.64-11.07)] and the Pfdhfr intermediate-to-high resistance, i.e., ≥ 2 Pfdhfr mutations [adjusted OR 3.45; 95% CI (1.18-10.07)]. There was no statistically significant association between the presence of the Pfdhfr intermediate-to-high resistance and parasite densities or both maternal haemoglobin level and anaemia.

conclusionThe data indicate that despite the possibility that IPTp-SP contributes to the selection of resistant parasites, it did not potentiate pregnancy-associated malaria morbidity, suggesting the continuation of SP use as IPTp in Burkina Faso.

Indexed as

MutationAdolescentAdultAnemiaAntimalarialsBurkina FasoDrug CombinationsFemaleHemoglobinsHumansMalaria, FalciparumPlasmodium falciparumPolymerase Chain ReactionPolymorphism, GeneticPolymorphism, Restriction Fragment LengthPregnancyAntimalarialsDrug Combinationsfanasil, pyrimethamine drug combinationHemoglobinsProtozoan ProteinsPyrimethamineSulfadoxineBurkina FasoDrug resistanceMalariaPregnancySulfadoxine–pyrimethamine

Identifiers

PMID28114990
PMCPMC5259838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.